NRX Pharmaceuticals (NRXP) Notes Payables (2019 - 2026)

NRX Pharmaceuticals (NRXP) has reported Notes Payables for 8 consecutive years, with $18.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Notes Payables rose 14.04% year-over-year to $18.6 million in Q2 2026; TTM through Jun 2026 was $18.6 million, a 14.04% increase from a year earlier, with the FY2025 full-year figure at $12.3 million, up 118.19% from the prior year.
• Notes Payables was $18.6 million for Q2 2026 at NRX Pharmaceuticals, up from $8.8 million in the prior quarter.
• Over five years, Notes Payables peaked at $18.6 million in Q2 2026 and troughed at $19000.0 in Q2 2022.
• A 5-year average of $8.8 million and a median of $9.2 million in 2023 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables slumped 99.92% in 2022 and surged 66700.0% in 2023, its largest moves.
• Over 5 years, Notes Payables stood at $7.7 million in 2022, then grew by 18.93% to $9.2 million in 2023, then tumbled by 38.45% to $5.6 million in 2024, then jumped by 118.19% to $12.3 million in 2025, then jumped by 50.76% to $18.6 million in 2026.
• The last three Notes Payables figures came in at $18.6 million (Q2 2026), $8.8 million (Q1 2026), and $12.3 million (Q4 2025), per Business Quant data.